2011年北京地区69家社区医院调节血脂药应用分析

目的:研究2011年北京地区69家社区医院调节血脂药的应用情况,为临床合理用药提供参考。方法:对参与"北京社区医院药物利用与评价研究课题"的69家社区医院2011年调节血脂药的应用情况进行统计。结果与结论:2011年北京地区69家社区医院应用的调节血脂药涵盖了羟甲基戊二酸辅酶A还原酶抑制剂(他汀类)、贝丁酸类、烟酸及其衍生物、其他降低胆固醇和三酰甘油药等多类药物,其中应用量最大、金额最多的药物集中在羟甲基戊二酸辅酶A还原酶抑制剂辛伐他汀和阿托伐他汀;共有53家药品生产厂供应,默沙东(中国)有限公司、北京嘉林药业股份有限公司和辉瑞制药有限公司分别凭借其优势产品辛伐他汀(舒降之)、阿托伐他汀钙(阿乐)和阿托伐他汀(立普妥)占据了应用排序前3位;各月调节血脂药均有应用,全年应用数量和金额较为稳定,冬季(11、12、1月)应用较多;郊区的社区医院调节血脂药的应用数量和金额明显高于市区的社区医院,二级医院调节血脂药的应用数量和金额约为一级医院的5～6倍。

Utilization of Lipid-regulating Drugs in 69 Community Hospitals of Beijing in 2011

OBJECTIVE: To investigate the utilization of lipid-regulating drugs in 69 community hospitals in Beijing in 2011 to provide references for clinical rational administration of this kind of drugs.METHODS: The utilization of lipid-regulating drugs in 69 community hospitals during 2011(there the research subject on drug utilization and evaluation in Beijing community hospitals was performed) was analyzed statistically.RESULTS & CONCLUSION: The lipid-regulating drugs used in the 69 community hospitals in Beijing in 2011 included HMG-CoA reductase inhibitors(statins),fibrates,niacin and its derivatives,drugs for lowering cholesterol level and triglycerides etc,with HMG-CoA reductase inhibitors-simvastatin and atorvastatin leading the list in terms of consumption quantity and consumption sum.The lipid-regulating drugs were purchased from 53 pharmaceutical manufacturers,with sivastatin(Zocor) from Merck Sharp & Dohme(China) Co.Ltd.,atorvastatin calcium from Beijing Jialin pharmaceutical Co.,Ltd.and atorvastatin(Lipitor) from Pfizer Pharmaceuticals Limited dominated the top three places.There was consumption of lipid-regulating drugs each month,which were mostly used in winter(Nov.,Dec.,and Jan.),and which were more frequently used in suburb community hospitals than in downtown community hospitals.The consumption(sum of money and quantity) of these drugs in grade-II hospital was about 5-6 times that in grade-I hospital.